

Thursday, September 23, 2010

Foyer

Registration

Lecture hall

Opening ceremony

Section I.

Medical Genomics

Coffee break / Accompanying exhibition

Section II.

Gene Therapy I.

Coffee break / Accompanying exhibition

Section III.

Gene Therapy II.

Friday, September 24, 2010

Section IV.

Vaccines and Adjuvans

Coffee break / Accompanying exhibition

Section V.

Immunotherapy

Lunch

Section VI.

Cell therapy

Coffee break / Accompanying exhibition

Section VII.

Round table on Modern therapies, Ethics and Regulatory issues

Saturday, September 25, 2010

Section VII

Short oral presentations of young scientist

Coffee break / Accompanying exhibition

Short presentations of selected posters

Closing ceremony

Section I.

Medical Genomics

Chairman: Ass. Prof. RNDr. Šárka Pospíšilová, Ph.D.

- 1. High-throughput genome analyses – new technologies**
Beneš V.
- 2. Identification of disease-causing genes using genomic techniques**
Kmoch S.
- 3. Application of genomic approaches in hematooncological research and diagnostics**
Pospíšilová Š.
- 4. Possibilities of residual disease monitoring in leukemia**
Haškovec C.
- 5. Genomic stability of stem cells – why should we care**
Hampl A.

Coffee break / Accompanying exhibition

Section II.

Gene Therapy I.

*Chairmen: Prof. MUDr. Vladimír Vonka, DrSc.
RNDr. Michal Šmahel, Ph.D.*

- 6. Gene therapy: hopes and problems**
Vonka V.
- 7. Retroviruses and construction of vectors suitable for gene therapy**
Svoboda J.
- 8. Non-viral vectors for gene therapy**
Miller A.D.
- 9. Minicircles: smart vectors for gene therapy**
Schleef M.

Coffee break / Accompanying exhibition

Section III.

Gene Therapy II.

*Chairmen: Prof. MUDr. Vladimír Vonka, DrSc.
RNDr. Michal Šmahel, Ph.D.*

- 10. Genetically modified mesenchymal cells**
Altaner Č.

11. Effect of Surface Termination on Photoluminescence of Nanodiamond

Nesládek M.

12. Gene therapy and immune response

Šmahel M.

13. Gain-of-function or loss-of-function: see the difference by SOLiD Next Generation Sequencing

Szilassy D.

14. Next Generation Sequencing – sekvenování ampliconů technologií Roche 454

Žák P.

Welcome party and classic music

Programme

Friday, September 24, 2010

Section IV.

Vaccines and Adjuvans

Chairman: RNDr. Jaroslav Turánek, CSc.

15. DNA vaccines

Stevenson F., Ottensmeyer C.

16. Immune responses towards mucosally recognised antigens

Mestecky J.

17. Liposome based recombinant vaccines and adjuvans

Turánek J.

18. Adjuvant properties of Bordetella adenylate cyclase toxoid"

Šebo P.

19. Targeting of DNA vaccines to mucosal diseases

Raška M.

Discussion

Coffee break / Accompanying exhibition

Section V.

Immunotherapy

Chairman: Prof. MUDr. Jaroslav Michálek, Ph.D.

20. A novel target for the immunotherapy of acute myeloid leukaemia

Guinn B.

21. RNA-modified dendritic cell vaccines for therapeutic vaccination of cancer: past, present and future

Van Tendeloo V.

22. New generation of IL-12 producing dendritic cells for cancer Immunotherapy

Michálek J.

23. Immunostimulatory effects of nanotherapeutics based on water-soluble carrier system

Říhová B.

24. Dendritic cell vaccination in prostate cancer

Bartůňková J.

Discussion

Lunch

Section VI.

Cell therapy

Chairman: Prof. MUDr. Eva Syková, DrSc.

25. Stem cells and the treatment of brain and spinal cord injury
Syková E.

26. Treatment of diabetes by cell transplantation
Saudek F.

27. Treatment of ischemic leg by stem cells
Jirkovská A.

28. Treatment of hepatic failure by hepatocytes
Koblihová E., Pantoflíček T., Ryska M.

29. Characterization of bone marrow mesenchymal stem cells of patients with critical limb ischemia
Altaner Č.

Discussion

Coffee break / Accompanying exhibition

Section VI.

Roundtable on Modern therapies, Ethics and Regulatory issues

*Moderators: Prof. MUDr. Vladimír Vonka, DrSc.,
Prof. MUDr. E. Syková, DrSc.
Prof. MUDr. J. Michálek, Ph.D.,
RNDr. J. Turánek, CSc.*

43. CLL-SPECIFIC RESEQUENCING MICROARRAY AS A TOOL FOR CLL RESEARCH AND DIAGNOSTICS

Lochmanova J., Tichy B., Plevova K., Dobe, P., Navrkalova V., Malcikova J., Rocnov, L., Mraz M., Zeleny J., Dvorakova B., Mayer J., Trbusek M., Pospisilova S.

44. PCR Detection of Mucormycetes in Hematooncological Patients

Hrncirova K., Lengerova M., Kocmanova I., Racil Z., Mayer J.

45. Immunological studies with mouse bcr-abl-transformed cells

Lučanský V., Sobotková E., Dušková M. Vonka V.

46. Manipulation of gene expression in chronic lymphocytic leukemia cells in vitro

Pavlova S., Kaucka M., Mraz M., Plevova K., Verner J., Mayer J., Bryja V., Pospisilova S.

47. Human medullary thyroid carcinoma cells are refractory to CD-AT-MS/5FC mediated bystander cytotoxicity

Kucerova L., Poturnajova M., Matuskova M.

48. Rituximab and calcium flux in neoplastic B-cells

Borský M., Loja T., Ionescu M., Klabusay M.

49. Surface polyvalent orthogonal functionalization of nanodiamonds

Tvrdoňová M., Cígler P., Ledvina M.

12.30 – 12.45 Closing ceremony

13.00 – 14.00 Lunch

Posters

1. Unique MEN2A mutation expressed high transforming potential in vitro and in vivo

Poturnajová M., Fekečsová S., Altanerová V.

2. The role of IgA1 O-glycans heterogeneity in mucosal immunity

Horynová M., Takahashi K., Renfrow M., Novak J., Weigl E., Raška M.

3. IDENTIFICATION OF CISTEINE DIOXYGENASE IN TRICHOPHYTON MENTAGROPHYTES

Kašperová A., Kunert J., Šebela M., Raška M.

4. INHIBITION OF DNA-PK AS A TOOL TO SENSITIZE CHRONIC LYMPHOCYTIC LEUKEMIA CELLS TO CHEMOTHERAPY-INDUCED DNA-DAMAGE

Rocnova L., Boehmova O., Brychtova Y., Pospisilova S., Mayer J., Trbusek M.

5. SIN-retroviral vectors containing anti-angiogenic genes in gene therapy of mouse xenograft tumors

Tyciakova S., Hlubinova K., Kucerova L.

6. Expansion of fat mesenchymal stem cells and their suicide gene-derivates for clinical application

Cihová M., Altanerová V., Altaner Č.

7. Cytotoxic effect of yCD-ATMSC/5FC on cancer cells cultivated in multicellular nodules

Bohovic R., Tyciakova S., Kucerova L.

8. ORGAN DAMAGE ASSOCIATED WITH OVERPRODUCTION OF GM-CSF BY GENE-MODIFIED MOUSE CELLS TRANSFORMED BY BCR-ABL FUSION GENE

Staněk L., Petráčková M., Dunder P., Šídlová J., Vonka V.

9. Oligonucleotide-mediated gene therapy

Bunce M.